First Light Asset Management LLC reduced its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 15.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 524,509 shares of the company’s stock after selling 97,729 shares during the period. Oxford Immunotec Global PLC makes up 3.0% of First Light Asset Management LLC’s portfolio, making the stock its 9th biggest position. First Light Asset Management LLC owned approximately 2.27% of Oxford Immunotec Global PLC worth $8,822,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Voya Investment Management LLC grew its stake in shares of Oxford Immunotec Global PLC by 16.0% in the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Oxford Immunotec Global PLC by 5.4% in the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock worth $1,161,000 after acquiring an additional 3,507 shares during the last quarter. Northern Trust Corp grew its stake in shares of Oxford Immunotec Global PLC by 20.0% in the second quarter. Northern Trust Corp now owns 243,961 shares of the company’s stock worth $4,104,000 after acquiring an additional 40,637 shares during the last quarter. Penn Capital Management Co. Inc. grew its stake in shares of Oxford Immunotec Global PLC by 51.6% in the second quarter. Penn Capital Management Co. Inc. now owns 179,415 shares of the company’s stock worth $3,018,000 after acquiring an additional 61,080 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Oxford Immunotec Global PLC by 6.8% in the second quarter. TIAA CREF Investment Management LLC now owns 76,094 shares of the company’s stock worth $1,280,000 after acquiring an additional 4,840 shares during the last quarter. 79.13% of the stock is currently owned by hedge funds and other institutional investors.

In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 27,168 shares of the business’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $15.94, for a total transaction of $433,057.92. Following the sale, the chief executive officer now owns 488,836 shares in the company, valued at approximately $7,792,045.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $15.82, for a total value of $47,460.00. Following the sale, the director now owns 18,000 shares in the company, valued at approximately $284,760. The disclosure for this sale can be found here. In the last quarter, insiders have sold 95,110 shares of company stock worth $1,578,027. Company insiders own 7.58% of the company’s stock.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 2.61% on Friday, reaching $16.80. The company’s stock had a trading volume of 149,331 shares. Oxford Immunotec Global PLC has a 12-month low of $11.71 and a 12-month high of $19.51. The firm has a 50 day moving average price of $16.10 and a 200-day moving average price of $15.51. The stock’s market cap is $387.68 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). The business had revenue of $26.10 million for the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.29) EPS. Equities research analysts expect that Oxford Immunotec Global PLC will post ($1.63) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (OXFD) is First Light Asset Management LLC’s 9th Largest Position” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-is-first-light-asset-management-llcs-9th-largest-position/1598764.html.

OXFD has been the topic of a number of recent research reports. Zacks Investment Research cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, August 30th. ValuEngine raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company reaffirmed a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday. BTIG Research began coverage on Oxford Immunotec Global PLC in a research report on Thursday. They set a “buy” rating and a $21.00 price objective on the stock. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $20.75.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.